Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin and Prednisolone for Retinal Vein Occlusion
NCT00500045Phase 3Terminated
- Start
- Feb 2007
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of niacin in central retinal vein occlusion (CRVO), hemiretinal vein occlusion (HRVO) and branch retinal vein occlusion (BRVO). Primary endpoint: Best Corrected Visual Acuity at 1 year. Started Feb 2007; status: terminated.
02
Drugs
niacin
03
Conditions
central retinal vein occlusion (CRVO)hemiretinal vein occlusion (HRVO)branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT00500045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500045.